Filing Flows › Vertex Pharmaceuticals (VRTX) › Operating margin
Vertex Pharmaceuticals (VRTX) operating margin by quarter
Vertex Pharmaceuticals' operating margin was 20.7% in Q3 2026 (third quarter 2026), -16.7 pts from Q2 2026. Over the last 7 quarters it ranged from 20.7% (Q3 2026) to 38.8% (Q2 2025).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 20.7% | -16.7 pts | -17.8 pts |
| Q2 2026 | 37.4% | -0.7 pts | -1.4 pts |
| Q1 2026 | 38.1% | +0.3 pts | +15.4 pts |
| Q4 2025 | 37.8% | -0.8 pts | — |
| Q3 2025 | 38.6% | -0.3 pts | — |
| Q2 2025 | 38.8% | +16.1 pts | — |
| Q1 2025 | 22.7% | — | — |
Q3 2026 at a glance
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vertex Pharmaceuticals' operating margin?
Vertex Pharmaceuticals' operating margin was 20.7% in Q3 2026 (third quarter 2026), -16.7 pts from Q2 2026.
How has Vertex Pharmaceuticals' operating margin changed?
Over the last 7 quarters it ranged from 20.7% (Q3 2026) to 38.8% (Q2 2025).
Q3 2026 results → · How Vertex Pharmaceuticals makes money →